Stocktoria
Calumet, Inc. /DE CLMT
Calumet, Inc. /DE (CLMT) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $4.1B at a -0.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.98 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-03-30 | HC Wainwright & Co. | Buy (main) |
| 2026-03-12 | Goldman Sachs | Buy (main) |
| 2026-01-30 | Goldman Sachs | Buy (main) |
| 2025-11-10 | HC Wainwright & Co. | Buy (reit) |
| 2025-10-22 | Goldman Sachs | Buy (main) |
| 2025-08-12 | UBS | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.006 |
| Retained earnings / assets | -0.585 |
| EBIT / assets | 0.04 |
| Equity / liabilities | -0.231 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLMT | Calumet, Inc. /DE | 6/9 | -1.84 | — | -1.2% |
| CVI | CVR ENERGY INC | 7/9 | 0.98 | 100.9 | -5.9% |
| IEP | ICAHN ENTERPRISES L.P. | 2/9 | — | — | -3.6% |
| DK | Delek US Holdings, Inc. | 4/9 | -0.2 | — | -9.5% |
| SUNC | SunocoCorp LLC | 4/9 | — | — | +11.1% |
| SUN | Sunoco LP | 5/9 | — | 25.8 | +11.1% |
| PBF | PBF Energy Inc. | 3/9 | 1.91 | — | -11.4% |
About Calumet, Inc. /DE
Calumet, Inc. manufactures, formulates, and markets a slate of specialty branded products and renewable fuels in North America and internationally. It operates through Specialty Products and Solutions; Performance Brands; and Montana/Renewables segments. The Specialty Products and Solutions segment manufactures and markets various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The Montana/Renewables segment processes geographically advantaged renewable feedstocks into renewable diesel, aviation fuel, and renewable naphtha. This segment also engages in the process of Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. The Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. It serves wholesale distributors and retail chains. Calumet, Inc. was founded in 1919 and is headquartered in Indianapolis, Indiana.
FAQ
Is CLMT financially healthy?
Calumet, Inc. /DE's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CLMT pay a dividend?
No, Calumet, Inc. /DE does not currently pay a dividend.
How profitable is CLMT?
In FY2025, Calumet, Inc. /DE had a net margin of -0.8%.
What is the analyst price target for CLMT?
The average Wall-Street price target for Calumet, Inc. /DE is $38.80, about 17.8% below the recent price, from 5 analysts (consensus: buy).
Is CLMT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Calumet, Inc. /DE: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.